Clinical Trial Update: A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 1-2 open-label study of AEG35156 in relapsed or refractory chronic lymphocytic leukemia and indolent B-cell lymphomas, which h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• AEG35156 (XIAP antisense oligonucleotide)

Snippet

Sponsor: Aegera Therapeutics | Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell | Phase 1, Phase 2 | Status: TERMINATED